CRXT Clarus Therapeutics Bullish ReversalCRXT Clarus Therapeutics had 3 green days after its sell-off to all time low.
This should signal a reversal pattern.
Clarus Therapeutics has the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions called JATENZO.
The fist target is the $1.1 private placement offering price and then the $2.10 resistance.
Few months ago they had another private placement at $4.96 per unit, so we can take that into consideration as well.
Needham & Company LLC has a Price Target of $8 for CRXT (that is the ultimate goal).
I think it can easily double from here.
Looking forward to read your opinion about it.
Clarustherapeutics
CRXT 900% Upside Potential According to this analyst Clarus Therapeutics Holdings, Inc. (CRXT) Announced Initiation of Phase 4 Clinical Trial of JATENZO, the first and only FDA-approved oral softgel for testosterone replacement therapy in adult male.
On 3/31/2022 Serge Belanger from Needham & Company LLC brokerage set a Buy Rating for CRXT and a Price Target of $8.00, which is 9 times higher than the current price.
I think it can easily double.
Looking forward to read your opinion about it.
